From:
Sent:
To:
Cc:
Subject:

Attachments:

Dear

Please find attached

When we submit the n the next couple of weeks with the most recent amendments we will send it as well. I will see with my regulatory colleagues if it best to share upon submission or only once we receive approval or confirmation from the appropriate authorities.

This is of course confidential documentation

Kind regards

From:

@ec.europa.eu
@ec.europa.eu>

To:

@curevac.com>

Cc
@ec.europa.eu
@ec.europa.eu
@ec.europa.eu>
@ec.europa.eu>

CAUTION: External Email - This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear

As discussed this morning, could you kindly share with us the 2<sup>nd</sup> version of your IB as seems very keen on it and then next week we'll share the updated version 3 with everyone as well?

Many thanks and kindest regards,




I trust this finds you well and that you had a very good weekend.

Some Steering Board members have asked us to look into the r vaccine candidates that are subject to an APA.

Would you have urrently in the pipeline?

Many thanks for your kind input on this.

Best wishes for a good week ahead,







Follow us on Twitter:
<a href="mailto:QEU Health">@EU Health</a>
<a href="mailto:QFood EU">@Food EU</a>